BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

stART Licensing, Inc. Grants License Rights to GTC Biotherapeutics (GTCB)


4/10/2007 12:23:58 PM

AUSTIN, Texas, April 10 /PRNewswire/ -- Start Licensing, Inc. ("Start") announced today that it has granted GTC Biotherapeutics, Inc. a non-exclusive license to Roslin Institute patents and patent applications. These applications include the foundational somatic cell nuclear transfer cloning technology developed at the Roslin Institute for cloning Dolly the sheep. The license agreement allows GTC use of nuclear transfer cloning techniques to generate transgenic animals that produce therapeutic proteins in their milk.

In exchange for the license rights, GTC paid a combined upfront fee of $500,000 in cash and stock, including $200,000 in cash to Start and $300,000 in shares of GTC stock split equally between Start and its parent company Exeter Life Sciences, Inc. Financial terms also include minimum annual royalty obligations, and royalties on product sales.

"We are pleased to enter into this licensing agreement with GTC," said Jonathan Thatcher, President of Start Licensing. "This agreement underscores the potential for animal cloning technologies in applications that improve human health."

About Start Licensing

Start is a joint venture of Geron Corporation and Exeter Life Sciences, Inc. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep. Start's licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.

About GTC Biotherapeutics

GTC develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In August 2006, ATryn(R), GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal. ATryn(R) is partnered with LEO Pharma A/S for development and commercialization in Europe, Canada, and the Middle East. Additional information is available on the GTC web site, http://www.gtc-bio.com.

Start Licensing, Inc.

CONTACT: Lisa Hanna, +1-202-466-9633, for Start Licensing, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES